Literature DB >> 19373692

Review of anti-VEGF therapy in proliferative diabetic retinopathy.

Maria Stephanie R Jardeleza1, Joan W Miller.   

Abstract

Proliferative diabetic retinopathy (PDR) is a visually significant complication of diabetes mellitus. Pan-retinal photocoagulation (PRP) remains the standard treatment of choice. However, adverse effects of and clinical barriers to PRP have led to exploration of alternative and adjunctive therapeutic strategies in the treatment of proliferative disease. Inhibition of ocular vascular endothelial growth factor (VEGF) has emerged as a promising treatment modality for PDR. This review summarizes results from published studies using intravitreal anti-VEGF agents singly and in combination with standard therapeutic regimens in the treatment of proliferative diabetic retinopathy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19373692     DOI： 10.1080/08820530902800330

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN： 0882-0538            Impact factor:   1.975


  37 in total

1.  Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.

Authors:  André Messias; José Afonso Ramos Filho; Katharina Messias; Felipe P P Almeida; Rogério A Costa; Ingrid U Scott; Florian Gekeler; Rodrigo Jorge
Journal:  Doc Ophthalmol       Date:  2012-03-29       Impact factor: 2.379

Review 2.  The mouse retina as an angiogenesis model.

Authors:  Andreas Stahl; Kip M Connor; Przemyslaw Sapieha; Jing Chen; Roberta J Dennison; Nathan M Krah; Molly R Seaward; Keirnan L Willett; Christopher M Aderman; Karen I Guerin; Jing Hua; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06       Impact factor: 4.799

3.  Intravitreal dobesilate in the treatment of choroidal neovascularisation associated with age-related macular degeneration: report of two cases.

Authors:  Pedro Cuevas; Luis Outeiriño; Carlos Azanza; Guillermo Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-09-03

Review 4.  Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy.

Authors:  Sayon Roy; Timothy S Kern; Brian Song; Caren Stuebe
Journal:  Am J Pathol       Date:  2016-11-12       Impact factor: 4.307

5.  A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study.

Authors:  Qader Motarjemizadeh; Naser Samadi Aidenloo; Siamak Sepehri
Journal:  Int Ophthalmol       Date:  2015-05-06       Impact factor: 2.031

Review 6.  Dietary hyperglycemia, glycemic index and metabolic retinal diseases.

Authors:  Chung-Jung Chiu; Allen Taylor
Journal:  Prog Retin Eye Res       Date:  2010-09-22       Impact factor: 21.198

7.  Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac).

Authors:  Takeshi Yoshida; Junsong Gong; Zhenhua Xu; Yanhong Wei; Elia J Duh
Journal:  Exp Eye Res       Date:  2011-11-19       Impact factor: 3.467

Review 8.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

9.  Retinal microangiopathy in a mouse model of inducible mural cell loss.

Authors:  Cammi N Valdez; Joseph F Arboleda-Velasquez; Dhanesh S Amarnani; Leo A Kim; Patricia A D'Amore
Journal:  Am J Pathol       Date:  2014-08-01       Impact factor: 4.307

10.  Current concepts in intravitreal drug therapy for diabetic retinopathy.

Authors:  Anant Pai; Maha M El Shafei; Osman A Z Mohammed; Mustafa Al Hashimi
Journal:  Saudi J Ophthalmol       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.